Literature for peptidase A02.007: feline immunodeficiency virus retropepsin

Summary Alignment Tree Sequences Sequence features Distribution Structure Literature Substrates

(References are filtered for relevance to Inhibitor. To remove the filter click here. See explanation.)

    2011
  1. Lin,Y.C., Perryman,A.L., Olson,A.J., Torbett,B.E., Elder,J.H. and Stout,C.D.
    Structural basis for drug and substrate specificity exhibited by FIV encoding a chimeric FIV/HIV protease
    Acta Crystallogr D Biol Crystallogr67, 540-548. PubMed  Europe PubMed DOI  S  I
  2. 2009
  3. Kontijevskis,A., Petrovska,R., Yahorava,S., Komorowski,J. and Wikberg,J.E.
    Proteochemometrics mapping of the interaction space for retroviral proteases and their substrates
    Bioorg Med Chem17, 5229-5237. PubMed  Europe PubMed DOI  V  I
  4. 2008
  5. Norelli,S., El Daker,S., D'Ostilio,D., Mele,F., Mancini,F., Taglia,F., Ruggieri,A., Ciccozzi,M., Cauda,R., Ciervo,A., Barreca,M.L., Pistello,M., Bendinelli,M. and Savarino,A.
    Response of feline immunodeficiency virus (FIV) to tipranavir may provide new clues for development of broad-based inhibitors of retroviral proteases acting on drug-resistant HIV-1
    Curr HIV Res6, 306-317. PubMed  Europe PubMed DOI  I
  6. 2004
  7. [YEAR:19-11-2004]de Rozieres,S., Swan,C.H., Sheeter,D.A., Clingerman,K.J., Lin,Y.C., Huitron-Resendiz,S., Henriksen,S., Torbett,B.E. and Elder,J.H.
    Assessment of FIV-C infection of cats as a function of treatment with the protease inhibitor, TL-3
    Retrovirology1, 38-38. PubMed  Europe PubMed DOI  I
  8. Huitron-Resendiz,S., de Rozieres,S., Sanchez-Alavez,M., Buhler,B., Lin,Y.C., Lerner,D.L., Henriksen,N.W., Burudi,M., Fox,H.S., Torbett,B.E., Henriksen,S. and Elder,J.H.
    Resolution and prevention of feline immunodeficiency virus-induced neurological deficits by treatment with the protease inhibitor TL-3
    J Virol78, 4525-4532. PubMed  Europe PubMed DOI  I
  9. 2003
  10. Lin,Y.C., Beck,Z., Morris,G.M., Olson,A.J. and Elder,J.H.
    Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases
    J Virol77, 6589-6600. PubMed  Europe PubMed DOI  I
  11. [YEAR:1-5-2003]Mak,C.C., Brik,A., Lerner,D.L., Elder,J.H., Morris,G.M., Olson,A.J. and Wong,C.H.
    Design and synthesis of broad-based mono- and bi- cyclic inhibitors of FIV and HIV proteases
    Bioorg Med Chem11, 2025-2040. PubMed  Europe PubMed DOI  I
  12. 2001
  13. Le,V.D., Mak,C.C., Lin,Y.C., Elder,J.H. and Wong,C.H.
    Structure-activity studies of FIV and HIV protease inhibitors containing allophenylnorstatine
    Bioorg Med Chem9, 1185-1195. PubMed  Europe PubMed DOI  I
  14. [YEAR:22-1-2001]Mak,C.C., Le,V.D., Lin,Y.C., Elder,J.H. and Wong,C.H.
    Design, synthesis, and biological evaluation of HIV/FIV protease inhibitors incorporating a conformationally constrained macrocycle with a small P3' residue
    Bioorg Med Chem Lett11, 219-222. PubMed  Europe PubMed DOI  I
  15. 2000
  16. [YEAR:1-1-2000]Li,M., Morris,G.M., Lee,T., Laco,G.S., Wong,C.H., Olson,A.J., Elder,J.H., Wlodawer,A. and Gustchina,A.
    Structural studies of FIV and HIV-1 proteases complexed with an efficient inhibitor of FIV protease
    Proteins38, 29-40. PubMed  Europe PubMed DOI  I
  17. 1999
  18. [YEAR:15-8-1999]Dominy,B.N. and Brooks,C.L., III
    Methodology for protein-ligand binding studies: application to a model for drug resistance, the HIV/FIV protease system
    Proteins36, 318-331. PubMed  Europe PubMed DOI  I
  19. 1998
  20. Kervinen,J., Lubkowski,J., Zdanov,A., Bhatt,D., Dunn,B.M., Hui,K.Y., Powell,D.J., Kay,J., Wlodawer,A. and Gustchina,A.
    Toward a universal inhibitor of retroviral proteases: comparative analysis of the interactions of LP-130 complexed with proteases from HIV-1, FIV, and EIAV
    Protein Sci7, 2314-2323. PubMed  Europe PubMed DOI  S  I
  21. [YEAR:3-2-1998]Lee,T., Laco,G.S., Torbett,B.E., Fox,H.S., Lerner,D.L., Elder,J.H. and Wong,C.H.
    Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo
    Proc Natl Acad Sci U S A95, 939-944. PubMed  Europe PubMed  I
  22. 1997
  23. Laco,G.S., Schalk-Hihi,C., Lubkowski,J., Morris,G., Zdanov,A., Olson,A., Elder,J.H., Wlodawer,A. and Gustchina,A.
    Crystal structures of the inactive D30N mutant of feline immunodeficiency virus protease complexed with a substrate and an inhibitor
    Biochemistry36, 10696-10708. PubMed  Europe PubMed DOI  S  I
  24. Schalk-Hihi,C., Lubkowski,J., Zdanov,A., Wlodawer,A., Gustchina,A., Laco,G.S. and Elder,J.H.
    Structure of the D30N active site mutant of FIV proteinase complexed with a statine-based inhibitor
    Tech Protein Chem8, 643-654. DOI  S  I
  25. 1995
  26. Wlodawer,A., Gustchina,A., Reshetnikova,L., Lubkowski,J., Zdanov,A., Hui,K.Y., Angleton,E.L., Farmerie,W.G., Goodenow,M.M., Bhatt,D., Zhang,L. and Dunn,B.M.
    Structure of an inhibitor complex of the proteinase from feline immunodeficiency virus
    Nat Struct Biol2, 480-488. PubMed  Europe PubMed  S  I